HomeBiotech

Biotech

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

September 24, 2024

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

September 24, 2024

Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024

Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024

September 23, 2024

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

September 23, 2024

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

September 23, 2024

Preclinical Research with Advanced Oncology Models and Immuno-oncology Services by Altogen Labs

Preclinical Research with Advanced Oncology Models and Immuno-oncology Services by Altogen Labs

September 21, 2024

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

September 21, 2024

FDA Roundup: September 20, 2024

FDA Roundup: September 20, 2024

September 21, 2024

Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024

Rakuten Medical Presented Research Results of Preclinical Studies for PD-L1-Targeted Photoimmunotherapy at The 83rd Annual Meeting of The Japanese Cancer Association 2024

September 20, 2024

UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

September 20, 2024

« 1 … 12 13 14 15 16 … 75 »